证券代码：300404 证券简称：博济医药 公告编号：2025-084 博济医药科技股份有限公司 关于控股股东及其一致行动人减持股份触及 1%及 5%整数倍 暨简式权益变动报告书的提示性公告 公司控股股东王廷春先生及其一致行动人赵伶俐、横琴广金美好基金管理有 限公司－广金美好费米十三号私募证券投资基金保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 截至 2021 年 6 月 30 日，王廷春及其一致行动人赵伶俐合计持有公司股份 100,729,642 股，占公司当时总股本的比例为 38.55%。自 2021 年 6 月 30 日至 2025 年 12 月 3 日，信息披露义务人因一致行动人内部划转、股权激励计划、权益分 派、股份减持和向特定对象发行股票等原因导致其所持股数量及持股比例发生变 动。具体变动情况如下： 1、本次权益变动性质为持股比例减少，不触及要约收购，也不会导致公司 控股股东及实际控制人发生变化。 2、本次权益变动后，公司控股股东、实际控制人王廷春先生及其一致行动 人赵伶俐女士、横 ...

Core Viewpoint - The announcement from Boji Pharmaceutical indicates that major shareholders Wang Tingchun, Zhao Lingli, and Feimi No. 13 plan to reduce their holdings by 8.4258 million shares, representing 2.18% of the total share capital [1] Shareholding Changes - The combined shareholding of the three major shareholders decreased from 38.55% on June 30, 2021, to 35% as of December 3, 2025, which accounts for 35.24% of the total share capital after excluding shares in the repurchase account [1] - The equity change triggers thresholds of 1% and 5% [1] Control and Implementation - This reduction in shareholding will not result in a change of control for the company [1] - The share reduction plan has not yet been fully implemented [1]

博济医药公告，信息披露义务人王廷春、赵伶俐及横琴广金美好基金管理有限公司－广金美好费米十三 号私募证券投资基金因股权激励计划、权益分派、股份减持和向特定对象发行股票等原因，合计持股比 例从38.55%减少至35.00%。 ...

Group 1 - On December 3, 2025, Boji Pharmaceutical had a block trade of 3.867 million shares, with a transaction value of 31.7829 million yuan, accounting for 36.16% of the total transaction value for the day [1] - The average transaction price was 8.22 yuan, representing a discount of 15.62% compared to the market closing price of 9.74 yuan [1] - The highest transaction price recorded was 8.68 yuan, while the lowest was 7.94 yuan [1] Group 2 - Specific transactions on December 3, 2025, included a sale at 7.94 yuan for 30.91 million shares by Ping An Securities and a sale at 8.68 yuan for 145.79 million shares by Tianfeng Securities [2] - Other notable transactions involved sales at 7.94 yuan for 110 million shares by Guotai Junan Securities and 100 million shares by Tianfeng Securities [2]

Core Viewpoint - The company, Boji Pharmaceutical, has not yet developed its own drugs but is providing clinical research services for various treatments related to influenza and other acute respiratory infections, leveraging AI technology to enhance efficiency and quality [1] Group 1 - The company is currently not engaged in the independent development of related drugs [1] - Boji Pharmaceutical offers clinical research services targeting different patient populations for treatments of type A influenza, common influenza, and other acute upper respiratory infections [1] - The company is actively utilizing AI technology to improve the efficiency and quality of its services [1]

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

一、 日常经营合同概况 2024 年 4 月 3 日，博济医药科技股份有限公司（以下简称"博济医药"、"公 司"、"乙方"）与广州瑞安博医药科技有限公司（以下简称"广州瑞安博"、"甲 方"）签订了《技术服务（委托）合同》，合同总金额为人民币 6,963 万元（含税）。 合同约定广州瑞安博委托博济医药组织开展"AR882 胶囊"治疗原发性痛风伴 高尿酸血症患者的Ⅱ/Ⅲ期临床试验研究服务。具体内容详见公司于 2024 年 4 月 8 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司签订日常经营合同的 自愿性披露公告》（公告编号：2024-029）。 证券代码：300404 证券简称：博济医药 公告编号：2025-083 博济医药科技股份有限公司 关于日常经营合同的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、 交易进展情况 该项目执行过程中，因项目情况变化，经双方友好协商，双方签订了《"化 药 1 类新药 AR882 胶囊Ⅱ/Ⅲ期临床试验技术服务（委托）合同"补充协议》（以 下简称"《补充协议》"），对原合同部分内容进行变更，并 ...

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the development paths of innovative drugs and the role of AI in drug research and development [1][2] - Industry experts emphasized the need for Chinese pharmaceutical companies to shift from "follower" to "leader" by addressing unmet medical needs and leveraging innovative technologies [1][2] Group 1: Conference Highlights - The conference theme was "Bay Area Innovation, Navigating New Journeys," discussing key topics such as dual circulation development, accelerated technology transfer, and compliance in global expansion [1] - Notable speakers included industry leaders and experts, highlighting the importance of innovation and internationalization as core drivers for Chinese pharmaceutical companies [2] Group 2: Regulatory and Industry Perspectives - The Director of the Guangdong Provincial Drug Administration stressed the importance of drug quality and safety, urging companies to strengthen regulatory compliance and communication with authorities to avoid approval delays [1] - The conference aimed to inject new vitality into the biopharmaceutical industry in the Greater Bay Area and across China, promoting high-quality development and attracting talent and projects [1]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the theme "Bay Area Innovation, Navigating New Journeys" [1] - Key topics discussed included the dual circulation development path for innovative drugs, acceleration of technology transfer, compliant global expansion, and the role of AI in empowering the entire drug development chain [1] Group 1 - The conference was co-hosted by the Guangdong Provincial Biopharmaceutical Innovation Technology Association and the Guangzhou Science and Technology Progress Foundation, with participation from various organizations including Boji Pharmaceutical Technology Co., Ltd. [1] - The event aimed to explore solutions for innovative drugs in the current complex environment, injecting new vitality and wisdom into the innovation development of the biopharmaceutical industry in the Greater Bay Area and nationwide [1] Group 2 - Notable attendees included prominent figures such as academician Zhong Nanshan, various directors from health authorities in Guangdong, Hong Kong, and Macau, and leaders from over 1,000 top scientists and industry leaders [2] - The conference provided a platform for discussing the future development and innovative practices in the biopharmaceutical sector within the Greater Bay Area [2]